GLP-1 Drug Lawsuits Grow to 4,000+ Cases as Courts Weigh Blindness and Stomach Injury Claims
Two separate federal MDLs targeting Ozempic, Wegovy, and Mounjaro are building toward pivotal expert hearings — but scant safety data makes it hard to know how often serious harms actually occur.
More than 4,000 federal lawsuits now allege that the blockbuster GLP-1 drugs — Ozempic, Wegovy, Mounjaro, and their siblings — caused serious injuries ranging from permanent blindness to life-altering stomach paralysis. The cases are piling up faster than the science can answer the question at their core: how often do these drugs actually cause serious harm?
The litigation runs on two parallel tracks in the Eastern District of Pennsylvania, both before U.S. District Judge Karen S. Marston. MDL 3094 covers gastrointestinal injuries — gastroparesis, bowel obstruction, and ileus — and had roughly 3,848 cases pending as of July 1, 2026, according to legaldesire.com. MDL 3163, a separate docket, addresses claims that the drugs triggered non-arteritic anterior ischemic optic neuropathy (NAION) — a condition involving sudden, often permanent vision loss resulting from diminished blood flow to the optic nerve; according to settlementrecord.com, that MDL had 247 pending actions as of the Judicial Panel on Multidistrict Litigation's October 1, 2026 report.
No settlements have been reached in either docket. No bellwether trials have been scheduled. No plaintiff has been paid. According to legaldesire.com, the litigation's next significant milestone is a Rule 702 expert hearing in MDL 3094, set for September 10–18, 2026, at which Judge Marston will determine whether scientific experts on both sides may testify on general causation, warning adequacy, and preemption — a decision that could either unravel thousands of cases or substantially intensify settlement pressure on Novo Nordisk and Eli Lilly.
The manufacturers named as principal defendants — Novo Nordisk, which makes Ozempic, Wegovy, and Rybelsus, and Eli Lilly, which makes Mounjaro and Zepbound — face failure-to-warn claims as the central theory in both MDLs. Design-defect theories were already dismissed in MDL 3094. The core allegation is that both companies knew or should have known about serious risks and failed to adequately warn patients and doctors.
Adverse event reports linked to these drugs have been analyzed in public databases, though voluntary reporting does not establish causation or reveal the true rate at which any event occurs in the broader population of users.
That data gap sits at the center of both the scientific and legal disputes. Clinical studies have described events like pancreatitis as rare, and EU regulators have estimated NAION occurs infrequently in patients on semaglutide. But those figures come with significant uncertainty, and post-marketing surveillance has well-known limitations in capturing events that may take months or years to manifest.
The regulatory picture is uneven. After reviewing adverse event reports, the FDA updated the Ozempic label in September 2023 to include ileus — a form of bowel obstruction — according to legaldesire.com. On NAION, the European Medicines Agency moved first: its safety committee determined in June 2025 that NAION is a very rare side effect of semaglutide and called for label revisions across the EU. As of the time of settlementrecord.com's reporting, the FDA had not required a NAION-specific warning on U.S. labels — a regulatory gap that plaintiffs' attorneys have made central to their failure-to-warn arguments.
The panel found the actions shared common factual questions about the development, testing, regulatory history, promotion, and labeling of GLP-1 RA drugs and their capacity to cause NAION.— Judicial Panel on Multidistrict Litigation
According to settlementrecord.com, a 2024 study in JAMA Ophthalmology by researchers at Massachusetts Eye and Ear and Harvard Medical School found that semaglutide patients faced a significantly higher likelihood of receiving a NAION diagnosis than patients taking other diabetes or weight-loss drugs. Conducted as a retrospective single-center cohort analysis, the study's authors urged that larger follow-up research be undertaken — a call that highlights how much the evidentiary picture remains incomplete even as the case count climbs.
When MDL 3094 was formally centralized in February 2024, only a few dozen suits existed. MDL 3163, covering NAION claims, was created on December 15, 2025, with 18 initial cases, and grew to 247 actions by October 2026. Neither MDL has issued a master complaint or set a bellwether trial schedule, and first trials in the GI docket are not expected before 2027, according to legaldesire.com.
For the GI cases, a 2025 ruling by Judge Marston raised the evidentiary bar considerably: to proceed, gastroparesis plaintiffs must demonstrate that their diagnosis is supported by a properly performed gastric emptying study. According to legaldesire.com, claims grounded only in reported symptoms, with no objective test results, are subject to dismissal.
By slowing the rate at which the stomach empties, GLP-1 receptor agonists help regulate blood sugar and appetite. Plaintiffs argue that same mechanism can go too far, causing severe and sometimes permanent gastrointestinal dysfunction. Approved uses for the drugs include type 2 diabetes treatment and, depending on the formulation, chronic weight management.
What happens at the September 2026 expert hearings will determine the trajectory of the larger GI docket. If Judge Marston excludes plaintiffs' experts, thousands of cases could collapse. If she admits them, the litigation moves meaningfully closer to trials and, potentially, settlement negotiations — though any resolution is still years away, and no official compensation figures exist. According to legaldesire.com, attorneys drawing on comparable drug litigation have projected that severe gastroparesis cases might settle in the $200,000–$500,000 range, moderate cases at $50,000–$150,000, and permanent vision loss cases potentially higher — though these are unofficial estimates, not outcomes.
Why it matters — Tens of millions of people take GLP-1 drugs, and the outcome of these two federal MDLs — particularly the September 2026 expert hearings — will shape both what warnings appear on the labels and whether patients who suffered serious injuries can recover damages.
⚠ Not yet confirmed
- Severe gastroparesis cases could resolve in the $200,000–$500,000 range; moderate cases at $50,000–$150,000; permanent vision loss cases potentially $500,000 or more.
- specific NPR-derived counts of NAION (1,000+) and pancreatitis (1,928) reports and total report volume
- specific pancreatitis incidence of 0.24% from meta-analyses
- specific EU NAION estimate of up to 1 in 10,000
Reported by legaldesire.com, settlementrecord.com
- Eli LillyAmerican pharmacist, Union Army officer, businessman, philanthropist